Cycuria Therapeutics has received public grant funding to expand its operations and development efforts. The exact amount remains undisclosed.

Apr 28, 2025•5 months ago

GrazTherapeuticsBiotechnologyHealth Care

Investors

Wieland Capital (Wpmb Gmb H)Aws (Austria Wirtschaftsservice Gesellschaft Mb H)Ffg (Forschungs Förderungs Gesellschaft)

Description

Cycuria Therapeutics, a Graz, Austria-based preclinical biotechnology company, received grant funding from FFG and AWS. This funding will be used to further its operations and development efforts for novel biologics targeting tumour cells. Cycuria's lead asset, CUR-101, aims to treat acute myeloid leukaemia. The grant follows a previous Seed investment from Wieland Capital.

Company Information

Company

Cycuria Therapeutics

Location

Graz, Styria, Austria

About

Cycuria Therapeutics is a preclinical stage biotechnology company based in Graz, Austria. The company is developing novel biologics that selectively target both tumour cells and tumour stem cells while preserving the creation of healthy new blood cells. Its lead asset, CUR-101, is a novel protein-based targeted therapy for acute myeloid leukaemia (AML). The therapeutic rationale behind its approach has potential applications in other blood cancers and hard-to-treat solid cancers.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns